User profiles for P. N. Durrington

Paul Durrington

Professor of Medicine, University of Manchester
Verified email at manchester.ac.uk
Cited by 61035

Paraoxonase and atherosclerosis

PN Durrington, B Mackness… - … , thrombosis, and vascular …, 2001 - Am Heart Assoc
There is considerable evidence that the antioxidant activity of high density lipoprotein (HDL)
is largely due to the paraoxonase-1 (PON1) located on it. Experiments with transgenic …

Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review

…, AR Ness, HJ Moore, HV Worthington, PN Durrington… - Bmj, 2006 - bmj.com
Objective To review systematically the evidence for an effect of long chain and shorter chain
omega 3 fatty acids on total mortality, cardiovascular events, and cancer. Data sources …

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

…, P Couture, J De Graaf, PN Durrington… - Journal of internal …, 2006 - Wiley Online Library
There is abundant evidence that the risk of atherosclerotic vascular disease is directly related
to plasma cholesterol levels. Accordingly, all of the national and transnational screening …

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised …

HM Colhoun, DJ Betteridge, PN Durrington, GA Hitman… - The Lancet, 2004 - thelancet.com
Background Type 2 diabetes is associated with a substantially increased risk of cardiovascular
disease, but the role of lipid-lowering therapy with statins for the primary prevention of …

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and …

…, A Altiner, E Bonora, PN Durrington… - European heart …, 2007 - academic.oup.com
Durrington, Robert Fagard, Simona Giampaoli, Harry Hemingway, Jan Hakansson,
Sverre Erik Kjeldsen, Mogens Lytken Larsen, Giuseppe Mancia, Athanasios J. Manolis …

Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein

MI Mackness, S Arrol, PN Durrington - FEBS letters, 1991 - Wiley Online Library
Oxidative modification of low‐density lipoprotein (LDL) enhances its uptake by macrophages
in tissue culture and in vivo may underly the formation of arterial fatty streaks, the …

Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase

MI Mackness, S Arrol, C Abbott, PN Durrington - Atherosclerosis, 1993 - Elsevier
We have investigated the Cu 2+ induced generation of lipid peroxides in low density lipoprotein
(LDL) incubated with high density lipoprotein (HDL) and with purified paraoxonase, an …

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy

…, H Schmidt, G Brabant, S Kumar, PN Durrington… - Nature …, 2000 - nature.com
The lipodystrophies are a group of disorders characterized by the absence or reduction of
subcutaneous adipose tissue. Partial lipodystrophy (PLD; MIM 151660) is an inherited …

Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus

…, PH Winocour, S Arrol, M Ishola, PN Durrington - Atherosclerosis, 1991 - Elsevier
The activity of serum paraoxonase, an enzyme located on high-density lipoprotein, has
been investigated in familial hypercholesterolaemia (FH) and insulin dependent diabetes …

Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins

MI Mackness, B Mackness, PN Durrington… - Current opinion in …, 1996 - journals.lww.com
Human serum paraoxonase is located on an HDL. It has the capacity to retard the accumulation
of lipid peroxides in LDL under oxidizing conditions in vitro. Paraoxonase has a genetic …